Biocon Limited

BSE: 532523 NSE: BIOCON
Biocon Limited - pharma in Bengaluru, Karnataka, India. FY 2026 financials & compliance.
CIN L24234KA1978PLC003417 Incorporated 29 November 1978 ROC Bangalore HQ Bengaluru, Karnataka, India
Active Listed - NSE: BIOCON · BSE: 532523 Public Limited Company pharma Fortune India 500 · #172 Nifty 500
Data last updated
Market Cap
₹53,829 Cr
BIOCON · NSE
Share Price
₹323.50
-2.06% today
Revenue
₹16,927 Cr
FY 2025-26 · +10.9% YoY
EBITDA
₹3,052 Cr
Margin 18.0%
Net Profit
₹389 Cr
FY 2025-26 · -59.3% YoY
P/E (TTM)
75.9x
P/B 1.6x
ROE
1.3%
ROCE 3.8%
Debt / Equity
0.61
Interest cover 90.4x

About Biocon Limited

Data last updated:

Biocon Limited is a public limited company based in Bengaluru, Karnataka, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 29 November 1978 and has been in existence for over 48 years.

Biocon is ranked #172 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Kiran Mazumdar-Shaw is #102 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN L24234KA1978PLC003417. Its GSTIN is 29AAACB7461R1ZZ (Karnataka). The company holds 25 GST registrations, of which 8 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 532523 and NSE: BIOCON.

The company has an authorised share capital of ₹900 Cr and a paid-up capital of ₹814.85 Cr. It is led by directors including Shreehas Pradeep Tambe (Managing Director) and Kiran Mazumdar Shaw (Whole-Time Director).

Its last annual general meeting (AGM) was held on 06 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 20th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹16,927 Cr, a growth of 10.9% compared to the previous year. For the same year it recorded a net profit of ₹388.82 Cr (net margin 2.3%) and EBITDA of ₹3,052.4 Cr (EBITDA margin 18%). The net worth stands at ₹34,032 Cr (up 57.2% YoY). Total assets are valued at ₹53,491 Cr (up 8% YoY).

The company has about 4,020 employees on its provident fund (EPFO) records. Its group structure includes 6 subsidiaries.

The company is associated with 1 brand: Biocon. As per MCA filings, the company has open charges of ₹207.63 Cr and satisfied charges of ₹2,010.35 Cr on record. Court records list 286 cases involving the company, including 214 filed by the company and 72 filed against it; 40 cases are pending. The company has 40 deals on record (37 market trades, 1 debt financing, 1 qip), with disclosed funding of ₹1,570 Cr; the latest was in September 2026. Its 9 peer companies in the Pharma industry (Contract Research, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Cipla Limited with revenue of ₹28,409 Cr. The company has 29 MSME Form 1 returns on record between 2018 and 2024, listing 9,947 overdue payments to 1,091 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website biocon.com.

Company details

CIN L24234KA1978PLC003417
Registration Number 003417
Incorporation Date 29 November 1978
ROC Bangalore
Listing Status Listed - Listed on NSE (BIOCON); Listed on BSE (532523)
Company Status Active
Date of Last AGM 06 August 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN history

Biocon has one previous CIN (Corporate Identification Number): L00309KA1978PLC003417. The current CIN is L24234KA1978PLC003417, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24234KA1978PLC003417Current
L00309KA1978PLC003417Previous
Key People
Shreehas Pradeep Tambe Managing Director Kiran Mazumdar Shaw Whole-Time Director Daniel Mark Bradbury Director

Recognitions & Rankings of Biocon

Fortune India 500 2025 edition
Rank#172
Total income
₹16,272 Cr
Profit
₹1,013 Cr
Last year #154
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#140
Valuation
₹44,360 Cr
2023 #162 2022 #129 2021 #103
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Biocon Limited's registered office is in Bengaluru, Karnataka. Its website is biocon.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    biocon.com
  • Social Media
  • Registered Address
    20th Km Hosur Road Electronic City, Bengaluru, Karnataka, India – 560100
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Biocon Limited, buy the company report.

Comprehensive company report
Biocon Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Biocon operates one associated brand: Biocon. Each brand links to its own profile.

BrandDescriptionWebsite
Biocon
Drug R&D services are provided for multiple therapeutic areas.biocon.com

Business activity

The main business activity of Biocon is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Biocon Limited, buy the company report.

Financials of Biocon Limited

FY 2025-26 filings available

Biocon Limited reported revenue of ₹16,927 Cr (up 10.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹16,927 Cr
+10.9% YoY
EBITDA
₹3,052 Cr
-3.6% YoY
Profit After Tax
₹389 Cr
-59.3% YoY
Net Worth
₹34,032 Cr
+57.2% YoY
Total Assets
₹53,490 Cr
+8.0% YoY
Total Debt
₹15,434 Cr
-15.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue16,92715,26214,75611,1748,1847,1436,300
Revenue growth+10.9%+3.4%+32.1%+36.5%+14.6%+13.4%-
EBITDA3,0523,1663,2032,0531,6521,5731,574
EBITDA margin+18.0%+20.8%+21.7%+18.4%+20.2%+22.0%+25.0%
Profit before tax4481,8871,5258979831,0681,186
Net profit389956978693747730690
Net profit margin+2.3%+6.3%+6.6%+6.2%+9.1%+10.2%+11.0%
EPS (₹)2.388.448.523.855.406.176.24
Balance sheet
Total assets53,49049,52343,17245,67017,44015,68511,816
Net worth34,03221,64419,78417,8678,4327,6276,706
Total debt15,43418,36216,27718,0195,1474,4812,715
Cash & bank3,1944,1202,2592,4001,7482,015999
Net working capital6,5726,9232,3575,0164,2633,5871,869
Cash flow
Cash from operations1,9944,0612,9541,8521,1771,1601,283
Cash from investing(1,883)(203)(1,002)(14,260)(1,662)(3,651)(1,505)
Cash from financing(924)(1,854)(2,333)13,0492422,564388
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,3364,5174,1734,2963,9424,4173,8213,590
Revenue growth (YoY)+10.0%+2.3%+9.2%+19.6%+14.8%---
Other income54.5052.5011793.0079.7057.3052.9058.50
EBITDA8349405408247491,078752685
EBITDA margin+19.4%+21.0%+13.1%+19.3%+19.2%+24.7%+19.9%+19.3%
Depreciation547513515473455436425420
Interest213232210272277212223226
Profit before tax128248(67.80)17196.9048715698.40
Tax(9.20)48.90(16.00)38.507.7027.4074.8071.30
Net profit137199(51.80)13389.2045981.1027.10
EPS (₹)0.870.791.070.650.262.870.21(0.13)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,3462,2432,1271,9931,7382,0281,988
Revenue growth+4.6%+5.4%+6.7%+14.7%-14.3%+2.0%-
EBITDA11.0017626323.5061.10312286
EBITDA margin+0.5%+7.8%+12.4%+1.2%+3.5%+15.4%+14.4%
Profit before tax51.006611502,971140359553
Net profit175(50.81)106(13.33)83.18278305
Net profit margin+7.5%-2.3%+5.0%-0.7%+4.8%+13.7%+15.3%
EPS (₹)0.235.070.9923.720.722.343.67
Balance sheet
Total assets28,35714,49213,07812,3338,2798,0247,584
Net worth27,08011,52410,91210,9168,0937,9077,537
Total debt1,1532,8762,0431,30176.901.904.00
Cash & bank91.70250586720689601375
Net working capital1,2101,0552,0071,5481,5501,2801,218
Cash flow
Cash from operations(180)624(123)21947.60478387
Cash from investing(6,580)(992)(295)(1,173)(302)(628)(189)
Cash from financing6,6024953441,03911227.80(129)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue624605621583537644563525
Revenue growth (YoY)+16.3%-6.1%+10.4%+11.0%+5.2%---
Other income64.8049.8074.8013461.3062.7067273.50
Total expenses564544744530516582532488
EBITDA60.8060.50(123)52.9020.6062.0031.3037.60
EBITDA margin+9.7%+10.0%-19.8%+9.1%+3.8%+9.6%+5.6%+7.2%
Depreciation38.4036.2034.0033.8033.3033.0033.8030.50
Interest17.3016.702.3067.2056.2056.7065.3059.70
Profit before tax69.9057.40(84.50)85.70(7.60)35.0060420.90
Tax17.706.40(8.10)14.800.7013.8019.9017.70

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4,3364,5174,1734,2963,9424,4173,8213,590
Revenue growth (YoY)+10.0%+2.3%+9.2%+19.6%+14.8%---
Other income54.5052.5011793.0079.7057.3052.9058.50
EBITDA8349405408247491,078752685
EBITDA margin+19.4%+21.0%+13.1%+19.3%+19.2%+24.7%+19.9%+19.3%
Depreciation547513515473455436425420
Interest213232210272277212223226
Profit before tax128248(67.80)17196.9048715698.40
Tax(9.20)48.90(16.00)38.507.7027.4074.8071.30
Net profit137199(51.80)13389.2045981.1027.10
EPS (₹)0.870.791.070.650.262.870.21(0.13)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue16,92715,26214,75611,1748,1847,1436,300
Revenue growth+10.9%+3.4%+32.1%+36.5%+14.6%+13.4%-
Other income3421,305866376213267229
Total expenses13,87512,09511,5539,1216,5325,5704,726
Employee cost3,5083,1442,6642,1811,8801,7411,459
EBITDA3,0523,1663,2032,0531,6521,5731,574
EBITDA margin+18.0%+20.8%+21.7%+18.4%+20.2%+22.0%+25.0%
Depreciation1,9571,6871,5691,113814715552
Interest99089797441967.6057.7064.90
Profit before tax4481,8871,5258979831,0681,186
Tax79.10457227254212222315
Net profit389956978693747730690
Net profit margin+2.3%+6.3%+6.6%+6.2%+9.1%+10.2%+11.0%
EPS (₹)2.388.448.523.855.406.176.24
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital810600600600600600600
Reserves & surplus33,32921,12219,18317,2677,8327,0276,106
Shareholders' funds (net worth)34,03221,64419,78417,8678,4327,6276,706
Minority interest2,5906,0685,4914,6221,038881677
Secured loans11,29312,70112,23013,7952,6222,2952,042
Unsecured loans4,1415,6614,0474,2242,5252,186674
Total debt15,43418,36216,27718,0195,1474,4812,715
Total liabilities53,49049,52343,17245,67017,44015,68511,816
Assets
Gross block48,07940,80437,93035,32111,23310,2219,147
Net block36,48631,96330,64429,4686,5696,3645,971
Capital work in progress6,9878,5087,9937,3174,1102,8002,196
Investments1,7791,1271,0002,0691,5881,952966
Inventories6,0864,9314,9444,2442,2981,8671,436
Sundry debtors5,9875,4886,2313,5732,0581,5031,224
Cash & bank balances3,1944,1202,2592,4001,7482,015999
Loans & advances1,2241,3001,4307901,0611,006809
Total current assets16,49015,83914,86411,0087,1656,3924,467
Total current liabilities9,9188,91612,5075,9922,9012,8052,598
Net working capital6,5726,9232,3575,0164,2633,5871,869
Total assets53,49049,52343,17245,67017,44015,68511,816
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,9249201,300654897825659
Net cash from operating activities1,9944,0612,9541,8521,1771,1601,283
Net cash from investing activities(1,883)(203)(1,002)(14,260)(1,662)(3,651)(1,505)
Net cash from financing activities(924)(1,854)(2,333)13,0492422,564388
Net change in cash(812)2,004(380)641(243)72.30165
Closing cash3,1944,1202,2592,4001,7482,015999
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.9%+3.4%+32.1%+36.5%+14.6%+13.4%-
EBITDA growth-3.6%-1.1%+56.0%+24.3%+5.0%-0.1%-
PBT growth-76.3%+23.7%+70.0%-8.8%-7.9%-10.0%-2.4%
Net income growth-59.3%-2.3%+41.2%-7.3%+2.4%+5.8%-
Revenue CAGR (3Y)+14.9%+23.1%+27.4%+21.1%+14.1%+20.1%+17.4%
EBITDA CAGR (3Y)+14.1%+24.2%+26.7%+9.3%+5.8%+23.8%+17.1%
Profitability & leverage
Net income margin+2.2%+9.4%+8.8%+5.8%+9.4%+11.9%+13.8%
Return on capital employed+3.8%+6.9%+6.4%+5.7%+7.6%+8.7%+12.2%
Return on net worth+1.3%+6.9%+6.9%+6.6%+10.8%+11.8%+13.6%
Debt / equity0.610.840.910.880.600.500.40
Long-term debt / equity0.460.670.770.750.500.400.32
Interest cover90.3860.6659.6344.568.076.726.35
Efficiency & per share
Fixed asset turnover0.380.390.400.480.760.740.78
Inventory turnover3.073.093.213.423.934.335.11
Debtors turnover2.952.603.013.974.605.245.01
EPS (₹)2.388.448.523.855.406.176.24
Dividend per share (₹)0.500.500.501.500.500.000.00
Book value per share (₹)210.60180.92164.77148.8170.2363.5555.87
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue624605621583537644563525
Revenue growth (YoY)+16.3%-6.1%+10.4%+11.0%+5.2%---
Other income64.8049.8074.8013461.3062.7067273.50
Total expenses564544744530516582532488
EBITDA60.8060.50(123)52.9020.6062.0031.3037.60
EBITDA margin+9.7%+10.0%-19.8%+9.1%+3.8%+9.6%+5.6%+7.2%
Depreciation38.4036.2034.0033.8033.3033.0033.8030.50
Interest17.3016.702.3067.2056.2056.7065.3059.70
Profit before tax69.9057.40(84.50)85.70(7.60)35.0060420.90
Tax17.706.40(8.10)14.800.7013.8019.9017.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,3462,2432,1271,9931,7382,0281,988
Revenue growth+4.6%+5.4%+6.7%+14.7%-14.3%+2.0%-
Other income3208502083,134187150366
Total expenses2,3352,0671,8651,9691,6771,7161,702
Employee cost467501452434368390345
EBITDA11.0017626323.5061.10312286
EBITDA margin+0.5%+7.8%+12.4%+1.2%+3.5%+15.4%+14.4%
Depreciation13712812111710810498.00
Interest14223719969.600.400.401.20
Profit before tax51.006611502,971140359553
Tax13.8051.6031.0012353.6078.30112
Net profit175(50.81)106(13.33)83.18278305
Net profit margin+7.5%-2.3%+5.0%-0.7%+4.8%+13.7%+15.3%
EPS (₹)0.235.070.9923.720.722.343.67
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital810600600600600600600
Reserves & surplus26,23711,00210,31210,3167,4937,3076,937
Shareholders' funds (net worth)27,08011,52410,91210,9168,0937,9077,537
Secured loans1752,2522,0411,29875.900.000.00
Unsecured loans9786242.003.501.001.904.00
Total debt1,1532,8762,0431,30176.901.904.00
Total liabilities28,35714,49213,07812,3338,2798,0247,584
Assets
Gross block3,2352,8392,5872,4802,2772,0981,993
Net block1,3811,114958961870798793
Capital work in progress541701560344285179152
Investments24,97811,3839,3189,2715,2805,4134,953
Inventories875836665560542431535
Sundry debtors1,0038291,048658701588573
Cash & bank balances91.70250586720689601375
Loans & advances146255399307209210462
Total current assets2,1162,1702,6972,2452,1401,8301,945
Total current liabilities9061,115690697590550727
Net working capital1,2101,0552,0071,5481,5501,2801,218
Total assets28,35714,49213,07812,3338,2798,0247,584
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash250122197111254375306
Net cash from operating activities(180)624(123)21947.60478387
Net cash from investing activities(6,580)(992)(295)(1,173)(302)(628)(189)
Net cash from financing activities6,6024953441,03911227.80(129)
Net change in cash(158)127(74.30)85.60(142)(122)69.30
Closing cash91.70250586720689601375
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.6%+5.4%+6.7%+14.7%-14.3%+2.0%-
EBITDA growth-93.7%-33.1%+1017.9%-61.5%-80.5%+9.3%-
PBT growth-92.3%+339.7%-94.9%+2026.8%-61.1%-35.1%+2.9%
Net income growth+445.0%-148.0%+894.4%-116.0%-70.0%-8.9%-
Revenue CAGR (3Y)+5.6%+8.9%+1.6%+0.1%-0.9%-5.7%-8.4%
EBITDA CAGR (3Y)-22.4%+42.2%-5.6%-56.5%-33.8%-0.6%-21.5%
Profitability & leverage
Net income margin+1.6%+27.2%+5.6%+142.9%+5.0%+13.8%+22.2%
Return on capital employed+1.6%+2.1%+2.6%+1.5%+1.7%+4.6%+5.2%
Return on net worth+0.9%-0.5%+1.0%-0.1%+1.1%+3.6%+4.2%
Debt / equity0.100.220.150.070.000.000.01
Long-term debt / equity0.060.190.150.070.000.000.01
Interest cover-112.75493.54140.40-74.52-0.850.190.64
Efficiency & per share
Fixed asset turnover0.770.830.840.840.790.990.87
Inventory turnover2.742.993.473.623.584.202.98
Debtors turnover2.562.392.492.932.703.492.70
EPS (₹)0.235.070.9923.720.722.343.67
Dividend per share (₹)0.500.500.501.500.500.000.00
Book value per share (₹)166.8596.6390.8890.9167.4065.8862.80

To see the full year-wise statements and ratios of Biocon Limited, buy the company report.

Board of directors of Biocon Limited

Biocon has 13 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Daniel Mark Bradbury
Also directs: Biocon Biologics Limited
Director01 Aug 20260 Years 2 MonthsCurrent
Ravi Rasendra Mazumdar
Also directs: Glenloch Properties LLP
Director08 Aug 200026 Years 2 MonthsCurrent
Kiran Mazumdar Shaw
Also directs: Glenloch Properties LLP, Biocon Biologics Limited, Trent Limited and 5 more
Whole-Time Director01 Apr 201016 Years 6 MonthsCurrent
Eric Vivek MazumdarDirector01 Nov 20214 Years 11 MonthsCurrent
Naina Lal Kidwai
Also directs: Upl Limited, Gland Pharma Ltd, Nayara Energy Limited and 1 more
Director28 Apr 20224 Years 5 MonthsCurrent
Atul Dhawan
Also directs: Uti Asset Management Company Limited, National Investment and Infrastructure Fund Limited
Director16 May 20242 Years 5 MonthsCurrent
Showing 6 of 13 current directors. View all directors

Peer comparison

Biocon Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Contract Research, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Cipla Limited₹28,409 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Zydus Lifesciences Limited₹23,511 Cr (FY 2025)19.0%Ahmedabad, Gujarat, India
Lupin Limited₹22,904 Cr (FY 2025)14.0%Mumbai, Maharashtra, India
Intas Pharmaceuticals Limited₹21,241 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Biocon Limitedthis company₹16,927 Cr (FY 2026)₹388.82 Cr2.3%10.9%4,020Bengaluru, Karnataka, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Alkem Laboratories Limited₹13,458 Cr (FY 2025)4.0%Mumbai, Maharashtra, India
Glenmark Pharmaceuticals Limited₹13,435 Cr (FY 2025)6.0%Mumbai, Maharashtra, India
Torrent Pharmaceuticals Ltd₹11,539 Cr (FY 2025)7.0%Ahmedabad, Gujarat, India
Serum Institute of India Private Limited₹10,854 Cr (FY 2025)-2.0%Pune, Maharashtra, India

To see the full peer comparison of Biocon Limited, buy the company report.

Auditor

Biocon Limited is audited by BSR & Co. LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
BSR & Co. LLPFY 2023101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 44.70%, foreign institutional investors hold 8.10%, domestic institutional investors hold 23.40% and retail and other public shareholders hold 23.80%.

Promoters: 44.70%DII (Domestic Institutional): 23.40%FII (Foreign Institutional): 8.10%Retail & Others: 23.80%
Sep 2026
QUARTER
44.70% Promoters
23.40% DII (Domestic Institutional)
8.10% FII (Foreign Institutional)
23.80% Retail & Others
Promoter holding - history
Now 44.70% · Sep 2026High 54.40% · Dec 2025Low 44.70% · Sep 2026
43%46.3%49.5%52.8%56%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 54.40%Mar 2026: 54.40%Jun 2026: 44.90%Sep 2026: 44.70%54.40%44.70%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters44.70%44.90%54.40%54.40%
Public55.30%55.10%45.60%45.60%

Charges & borrowings

Open charges
₹207.63 Cr
Satisfied charges
₹2,010.35 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹197.50 Cr
Department of Biotechnology₹10.13 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
07 Nov 2022100641248Hdfc Bank Limited₹197.5 CrOpen
29 Jun 201110300393Department of Biotechnology₹4.43 CrOpen
12 Nov 201010255822Department of Biotechnology₹5.71 CrOpen
28 Apr 2023100775922Others₹500 CrSatisfied
12 Feb 2023100825122Others₹1,070 CrSatisfied

To see the full charge records of Biocon Limited, buy the company report.

Total charge records: 9 View all charges

Deals & funding

Biocon Limited has 40 deals on record (37 market trades, 1 debt financing, 1 qip), with disclosed funding of ₹1,570 Cr; the latest was in September 2026.

Total deals
40
Market trades
37
Debt financing
1
QIP
1
Acquisition
1
Disclosed funding
₹1,570 Cr

Deals on record (5 of 40)

WhenDealAmountParties
Sep 2026Market trade₹638.38 CrSeller: Activ Pine LLP
Sep 2026Market trade₹638.38 CrBuyer: Icici Prudential Mutual Fund, Sbi Mutual Fund, Aditya Birla Sun Life Mutual Fund
Seller: Activ Pine LLP
Jul 2026Market trade₹1,814.3 CrBuyer: Icici Prudential Mutual Fund, Kotak Mahindra Mutual Fund, Hdfc Mutual Fund
Seller: Mylan Inc.
Jul 2026Market trade₹1,839.34 CrBuyer: Icici Prudential Mutual Fund, Hdfc Mutual Fund, Kotak Mahindra Mutual Fund
Seller: Mylan Inc.
Jun 2025QIP₹4,500 CrInvestors: Others - Biocon Limited, HDFC Life Insurance Company Limited , Sbi Contra Fund

To see the full deal history of Biocon Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Biocon Limited was last rated by Icra on 29 Jan 2021.

Rating agencyRated onRating
Icra29 Jan 2021

To see the full credit ratings and regulatory alerts of Biocon Limited, buy the company report.

MSME payment delays

Biocon Limited has 29 MSME Form 1 returns on record between 2018 and 2024, listing 9,947 overdue payments to 1,091 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 1,091)

SupplierAmount dueDue sinceReported on
an individual supplier
Stellent Systems Private Limited
an individual supplier
Adeep Life Sciences Private Limited
Accrete Pharmaceuticals Private Limited

To see the full MSME payment records of Biocon Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Biocon has 6 subsidiary companies. This group structure data is as of FY 2022. The table lists each entity with its relationship and holding.

6
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Syngene International LimitedL85110KA1993PLC014937
Biocon Biologics LimitedU24119KA2016FLC093936
Biocon Pharma LimitedU24232KA2014PLC077036
Biocon Biosphere LimitedU24304KA2019PLC130965
Biofusion Therapeutics LimitedU73100KA2021PLC145487
Biocon AcademyU80301KA2013NPL072272

To see the full group structure of Biocon Limited, buy the company report.

Employees & EPFO

Biocon Limited has a workforce of 4,020 employees on its EPFO records as of Apr 08, 2024, across 1 active EPFO establishment.

Employee count
4,020
Active EPFO establishments
1
Employee growth
5.87%

GST

Biocon has 25 GST registrations: 8 active and 17 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
25
Active
8
Cancelled / inactive
17
GSTINStateStatusRegistered on
29AAACB7461R1ZZKarnatakaActive01 Jul 2017
29AAACB7461R2ZYKarnatakaActive05 Jul 2017
29AAACB7461R3ZXKarnatakaActive07 Jul 2017
29AAACB7461R4ZWKarnatakaActive12 Jul 2017

To see the full GST registrations and return filing status of Biocon Limited, buy the company report.

Recent activity

Biocon Limited has 50 board changes on record since 1998: 32 appointments and 18 cessations. The latest: Arun Suresh Chandavarkar was appointed as Director on 01 Aug 2026.

AGM
Biocon Limited last Annual general meeting of members was held on 06 Aug 2026 as per latest MCA records.
Appointed
Arun Suresh Chandavarkar was appointed as Director.
Appointed
Daniel Mark Bradbury was appointed as Director.
Appointed
Nivruti Rai was appointed as Director.
Appointed
Peter Baron Piot was appointed as Director.
Appointed
Rajiv Malik was appointed as Director.
Appointed
Thomas Jason Roberts was appointed as Director.
Appointed
Shreehas Pradeep Tambe was appointed as Managing Director.
Filing
Biocon Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Bangalore.
Charges
A charge registered on 28 Apr 2023 via Charge ID 100775922 with Others was fully satisfied on 05 Jan 2026.
Charges
A charge registered on 12 Feb 2023 via Charge ID 100825122 with Others was fully satisfied on 01 Oct 2025.
Ceased
Ekta Agarwal ceased to be Company Secretary.

57 earlier events are in the company report.

News

Biocon: Company Gets Early Launch Date For Pertuzumab Biosimilar Pebrilzo, U.S. Launch Expected In Q3 CY2028.
14 Oct 2026 · Exchange Update
BIOCON: Rs. 39.04 Crores NSE Block Trade; for ~ 1,057,554 Shares, at Rs. 369.20
06 Oct 2026 · Exchange Update
Biocon: Biocon Malaysia Gets MHRA Approval For New Drug Product Fill Finish Unit For Insulins
25 Sep 2026 · Exchange Update
Biocon: Co's Pertuzumab Is Now The First Biosimilar To Receive An EMA CHMP Approval Recommendation Using A New Customized Clinical Method.
21 Sep 2026 · Exchange Update

From our blog

Frequently asked questions

Biocon is an active public limited company based in Bengaluru, Karnataka, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 29 November 1978 (48+ years old) and is registered under CIN L24234KA1978PLC003417. Listed on BSE: 532523 and NSE: BIOCON.

Biocon reported revenue of ₹16,927 Cr for FY 2025-26 (up 10.9% YoY) based on consolidated financials.

Biocon has 13 current directors:

The latest financial statements of Biocon on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 06 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Biocon is 29AAACB7461R1ZZ, registered in Karnataka. The company has 25 GST registrations in all, of which 8 are active and 17 are cancelled or inactive. Other active GSTINs include 29AAACB7461R2ZY (Karnataka), 29AAACB7461R3ZX (Karnataka), 29AAACB7461R4ZW (Karnataka).

The CIN (Corporate Identification Number) of Biocon is L24234KA1978PLC003417. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Biocon is a listed company as per MCA records. Its shares are listed on both BSE (code: 532523) and NSE (symbol: BIOCON).

Biocon has 286 court cases on record: 214 filed by the company and 72 filed against it. 40 are pending. Most are in the district courts.

Biocon was incorporated on 29 November 1978, making it 48+ years old. It is registered with the Registrar of Companies, Bangalore.

Biocon has 40 deals on record (37 market trades, 1 debt financing, 1 qip), with disclosed funding of ₹1,570 Cr; the latest was in September 2026.

The peers of Biocon by revenue are Cipla Limited, Zydus Lifesciences Limited, Lupin Limited, Intas Pharmaceuticals Limited, Hetero Labs Limited and 4 more, all in the Pharma industry (Contract Research, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Arun Suresh Chandavarkar was appointed as Director on 01 Aug 2026. Daniel Mark Bradbury was appointed as Director on 01 Aug 2026. Nivruti Rai was appointed as Director on 01 Aug 2026. Biocon has 50 board changes on record in total.